| Autor: |
Tina S Ipe, Blessing Ugwumba, Horace J Spencer, Tuan Le, Terry Ridenour, John Armitage, Stefanie Ryan, Shanna Pearson, Atul Kothari, Naveen Patil, Ryan Dare, Juan C R Crescencio, Anand Venkata, Jennifer Laudadio, Khalid Mohammad, Naznin Jamal, John Thompson, Hailey McNew, McKenzie Gibbs, Steve Hennigan, Stan Kellar, Keith Reitzel, Brandon E Walser, Amanda Novak, Brian Quinn |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Laboratory medicine. 53(6) |
| ISSN: |
1943-7730 |
| Popis: |
Importance Many therapies are used to treat COVID-19, the disease caused by the virus SARS-CoV-2, including convalescent plasma. The clinical utility of using 2 units of convalescent plasma for COVID-19 hospitalized patients is not fully understood. Objective Many therapies are used to treat COVID-19, the disease caused by the virus SARS-CoV-2, including convalescent plasma. The clinical utility of using 2 units of convalescent plasma for COVID-19 hospitalized patients is not fully understood. Our study aims to determine the safety and efficacy of treating hospitalized COVID-19 patients with 2 units of COVID-19 convalescent plasma (CCP). Method This was a retrospective study of Arkansas patients treated with CCP using the (US) Food and Drug Administration (FDA) emergency Investigational New Drug (eIND) mechanism from April 9, 2020, through August 9, 2020. It was a multicenter, statewide study in a low-resource setting, which are areas that lack funding for health care cost coverage on various levels including individual, family, or social. Adult patients (n = 165, volunteer sample) in Arkansas who were hospitalized with severe or life-threatening acute COVID-19 disease as defined by the FDA criteria were transfused with 2 units of CCP (250 mL/unit) using the FDA eIND mechanism. The primary outcome was 7- and 30-day mortality after the second unit of CCP. Results Unadjusted mortality was 12.1% at 7 days and 23.0% at 30 days. The unadjusted mortality was reduced to 7.7% if the first CCP unit was transfused on the date of diagnosis, 8.7% if transfused within 3 days of diagnosis, and 32.0% if transfused at or after 4 or more days of diagnosis. The risk of death was higher in patients that received low, negative, or missing titer CCP units in comparison to those that received higher titer units. Conclusion The provision of 2 units of CCP was associated with a reduction in mortality in patients treated with high titer units within 3 days of COVID-19 diagnosis. Given the results, CCP is a viable, low-cost therapy in resource-constrained states and countries. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
